Eversource Energy (ES) Analysts See $0.76 EPS; Globeflex Capital LP Increased Vanda Pharmaceuticals (VNDA) Position By $437,800

Eversource Energy (NYSE:ES) Logo

Analysts expect Eversource Energy (NYSE:ES) to report $0.76 EPS on February, 28.They anticipate $0.01 EPS change or 1.33% from last quarter’s $0.75 EPS. ES’s profit would be $240.84 million giving it 22.94 P/E if the $0.76 EPS is correct. After having $0.93 EPS previously, Eversource Energy’s analysts see -18.28% EPS growth. The stock decreased 0.75% or $0.53 during the last trading session, reaching $69.75. About 357,892 shares traded. Eversource Energy (NYSE:ES) has risen 7.29% since February 13, 2018 and is uptrending. It has outperformed by 7.29% the S&P500. Some Historical ES News: 31/05/2018 – CONNECTICUT WATER SERVICE – HAS RIGHT UNDER AMENDED MERGER DEAL TO REVIEW & NEGOTIATE ALTERNATIVE PROPOSALS RECEIVED FROM THIRD PARTIES UNTIL JULY 14; 04/05/2018 – EVERSOURCE ENERGY SAYS “REITERATES THAT EVERSOURCE’S $63.50 PER SHARE PROPOSAL” FOR CONNECTICUT WATER SERVICE “OFFERS A HIGHER PRICE”; 19/04/2018 – Eversource: Sent Follow-Up Communication to Connecticut Water Expressing Continued Interest on April 17; 27/04/2018 – EVERSOURCE REAFFIRMS COMMITMENT TO ACQUIRE CONNECTICUT WATER; 20/04/2018 – Power Utility Eversource Looks to Double Down on Its Water Bet; 16/05/2018 – DEEP ECO: Eversource May Face Pressure, Industry Falls in April; 19/04/2018 – CONNECTICUT WATER CONFIRMS RECEIPT OF PROPOSAL FROM EVER; 09/03/2018 – Boston Channel: Eversource: ‘Substantially complete power restoration’ by Sat. evening; 03/04/2018 – ORSTED ORSTED.CO SAYS BAY STATE WIND, ITS PARTNERSHIP WITH EVERSOURCE ES.N , HAS AGREED WITH EEW TO OPEN AND STAFF A MASSACHUSETTS FACILITY TO MANUFACTURE OFFSHORE WIND COMPONENTS; 28/04/2018 – Connecticut Water Says Board Determined Eversource Bid Not ‘Superior Proposal’

Globeflex Capital LP increased Vanda Pharmaceuticals Inc (VNDA) stake by 31.12% reported in 2018Q3 SEC filing. Globeflex Capital LP acquired 19,900 shares as Vanda Pharmaceuticals Inc (VNDA)’s stock rose 57.10%. The Globeflex Capital LP holds 83,843 shares with $1.92 million value, up from 63,943 last quarter. Vanda Pharmaceuticals Inc now has $951.44M valuation. The stock decreased 1.47% or $0.27 during the last trading session, reaching $18.14. About 580,551 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 106.26% since February 13, 2018 and is uptrending. It has outperformed by 106.26% the S&P500. Some Historical VNDA News: 14/03/2018 – Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stk; 02/05/2018 – Vanda Pharmaceuticals 1Q EPS 6c; 20/05/2018 – Vanda Insights Doesn’t See U.S. Oil Sanctions Against Venezuela (Video); 15/05/2018 – Consonance Capital Management Buys 5.9% of Vanda Pharma; 15/03/2018 – Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stkat $17/Share; 09/04/2018 – Vanda Pharma Closes Below 200-Day Moving Average: Technicals; 02/05/2018 – VANDA PHARMA SEES FY ADJ. OPERATING EXPENSES $163M TO $173M; 23/05/2018 – HETLIOZĀ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel; 02/05/2018 – Vanda Pharmaceuticals: Reiterates Prior 2018 Fincl Guidance; 02/05/2018 – Vanda Pharmaceuticals 1Q Rev $43.6M

Among 6 analysts covering Eversource Energy (NYSE:ES), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Eversource Energy had 9 analyst reports since September 11, 2018 according to SRatingsIntel. The rating was maintained by Wells Fargo on Monday, September 17 with “Outperform”. The company was maintained on Tuesday, September 11 by Morgan Stanley. The stock of Eversource Energy (NYSE:ES) has “Equal-Weight” rating given on Friday, September 21 by Morgan Stanley. Citigroup maintained Eversource Energy (NYSE:ES) on Tuesday, September 25 with “Neutral” rating. The firm earned “Buy” rating on Thursday, January 31 by Goldman Sachs. The stock of Eversource Energy (NYSE:ES) earned “Equal-Weight” rating by Morgan Stanley on Tuesday, February 12. The rating was maintained by Morgan Stanley with “Equal-Weight” on Thursday, October 11. Barclays Capital maintained it with “Equal-Weight” rating and $66 target in Monday, November 19 report. The stock of Eversource Energy (NYSE:ES) earned “Outperform” rating by Credit Suisse on Tuesday, December 4.

More notable recent Eversource Energy (NYSE:ES) news were published by: Seekingalpha.com which released: “Eversource Energy declares $0.535 dividend – Seeking Alpha” on February 06, 2019, also Seekingalpha.com with their article: “Eversource buys 50% stake in offshore wind assets in $225M deal – Seeking Alpha” published on February 08, 2019, Gurufocus.com published: “Mario Gabelli’s Gabelli Utilities Fund 4th Quarter Commentary – GuruFocus.com” on February 04, 2019. More interesting news about Eversource Energy (NYSE:ES) were released by: Seekingalpha.com and their article: “Stocks To Watch: Disney, Alphabet And Super Bowl Players – Seeking Alpha” published on February 02, 2019 as well as Seekingalpha.com‘s news article titled: “Eversource Energy (ES) Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: November 02, 2018.

Eversource Energy, a public utility holding company, engages in the energy delivery business. The company has market cap of $22.10 billion. The firm operates in three divisions: Electric Distribution, Electric Transmission, and Natural Gas Distribution. It has a 21.33 P/E ratio. It is involved in the generation, transmission, and distribution of electricity; and distribution of natural gas.

Among 6 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Vanda Pharmaceuticals had 11 analyst reports since August 23, 2018 according to SRatingsIntel. On Tuesday, October 16 the stock rating was maintained by Citigroup with “Buy”. As per Thursday, December 6, the company rating was maintained by JMP Securities. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, December 11. The firm has “Overweight” rating by Cantor Fitzgerald given on Tuesday, December 4. The stock has “Neutral” rating by Cantor Fitzgerald on Wednesday, February 6. Oppenheimer downgraded it to “Perform” rating and $29 target in Tuesday, December 11 report. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Citigroup on Friday, December 7. The rating was maintained by Oppenheimer with “Outperform” on Friday, September 21.

Since January 2, 2019, it had 0 insider purchases, and 4 selling transactions for $751,326 activity. Reverberi Gian Piero also sold $30,042 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday, January 2. $159,810 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was sold by Birznieks Gunther. The insider Kelly James Patrick sold $159,811. Polymeropoulos Mihael Hristos also sold $401,663 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares.

Globeflex Capital LP decreased Trueblue Ord (NYSE:TBI) stake by 64,715 shares to 77 valued at $2,000 in 2018Q3. It also reduced Big Lots Inc (NYSE:BIG) stake by 16,450 shares and now owns 45 shares. Carrizo Oil & Co Inc (NASDAQ:CRZO) was reduced too.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Seekingalpha.com which released: “Vanda Pharmaceuticals Q4 2018 Earnings Preview – Seeking Alpha” on February 12, 2019, also Globenewswire.com with their article: “Vanda Pharmaceuticals Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws – GlobeNewswire” published on February 11, 2019, Prnewswire.com published: “Wolf Popper LLP Announces Investigation on Behalf of Investors in Vanda Pharmaceuticals Inc. – PRNewswire” on February 12, 2019. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Nasdaq.com and their article: “Health Care Sector Update for 02/06/2019: NVLN, AGLE, VNDA, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” published on February 06, 2019 as well as Businesswire.com‘s news article titled: “INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Vanda Pharmaceuticals Inc. Investors (VNDA) – Business Wire” with publication date: February 11, 2019.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart